This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Primärliteratur
Dorr RT, Alberts DS, Einspahr J, et al: Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes. Cancer Treat Rep 71: 267–272, 1987.
Buesa JM, Gracia M, Valle M, et al: Phase I trial of intermittent high-dose dacarbazine. Cancer Treat Rep 68: 499–504, 1984.
Beck TM, Hart NE, Smith CE: Photosensitivity reaction following DTIC administration: report of two cases. Cancer Treat Rep 64: 725–726, 1980.
Baird GM, Willoughby ML: Photodegradation of dacarbazine. The Lancet 2: 681, 1978.
Koriech O, Shukla V: Reduced toxicity of DTIC with administration in the dark. Proc AACR-ASCO 21: 168, 1980.
Sekundärliteratur
Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.
Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6. Auflage: 1–17, 1999.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 1, 2. Auflage: A42–44, 1997.
Gain M, Melzer S, Meyer-Jürshof A, et al: Dacarbazin: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 1, 2. Auflage: 30–31, 1997.
Ignoffo RI, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.
Fachinformation Dacarbazin medac (Österreich), Medac, Jänner 1998.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.
Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.
Holmes BC: Administration of cancer chemotherapy agents. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 57–94, 1994.
Dorr RT, Von Hoff DD: Drug monographs: dacarbazine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 343–349, 1994.
EG–Sicherheitsdatenblatt, Version 94/11, Medac.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Barth J: Paravasate und deren Behandlung. In: Barth J (Hrsg) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, Kap. VI-3: 1–9, 2000.
Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemitherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2002). Dacarbazin. In: Paravasation von Zytostatika. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3799-4_17
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3799-4_17
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3800-7
Online ISBN: 978-3-7091-3799-4
eBook Packages: Springer Book Archive